| Date | Title | Description |
| 01.04.2025 | Sobi's Annual General Meeting: A Look Ahead | The Annual General Meeting (AGM) of Swedish Orphan Biovitrum AB (Sobi) is set for May 8, 2025. This meeting is a pivotal moment for shareholders, a chance to steer the ship of this biopharma company. Sobi, known for its focus on rare diseas... |
| 01.04.2025 | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Tue, Apr 01, 2025 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual Ge... |
| 31.03.2025 | Sobi publishes Annual and sustainability report for 2024 | Sobi publishes Annual and sustainability report for 2024
Mon, Mar 31, 2025 11:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi h... |
| 19.03.2025 | Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress | Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress
Wed, Mar 19, 2025 08:00 CET Report this content
Sobi® (STO: SOBI), today announced a researc... |
| 01.03.2025 | New Frontiers in Cancer and Rare Disease Treatment: A Look at Recent FDA Approvals | In the ever-evolving landscape of medicine, two recent developments stand out like beacons of hope. The U.S. Food and Drug Administration (FDA) has granted Priority Review status to two groundbreaking therapies: TLX250-CDx for kidney cancer... |
| 27.02.2025 | US FDA grants Priority Review to Sobis supplemental Biologics Licence Application (sBLA) for Gamifant ® (emapalumab-lzsg) | US FDA grants Priority Review to Sobis supplemental Biologics Licence Application (sBLA) for Gamifant ® (emapalumab-lzsg)
Thu, Feb 27, 2025 08:00 CET Report this content
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Adminis... |
| 27.02.2025 | US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant ® (emapalumab-lzsg) | US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant ® (emapalumab-lzsg)
Thu, Feb 27, 2025 08:00 CET Report this content
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Admini... |
| 20.02.2025 | EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN | EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
Thu, Feb 20, 2025 08:00 CET Report this content
Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has ... |
| 07.02.2025 | Sobi and Medidata: Two Titans Transforming Healthcare with Innovation and Insight | In the ever-evolving landscape of healthcare, two companies stand out: Sobi and Medidata. Each is a beacon of innovation, charting new territories in biopharmaceuticals and life sciences. Their recent reports reveal not just numbers, but a ... |
| 05.02.2025 | Sobi publishes Q4 2024 report: A solid ending to a strong year | Sobi publishes Q4 2024 report: A solid ending to a strong year
Wed, Feb 05, 2025 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024
Fourth Quarter 2024
• Total rev... |
| 28.01.2025 | Sobi’s latest haemophilia research to be presented at EAHAD 2025 | Sobi’s latest haemophilia research to be presented at EAHAD 2025
Tue, Jan 28, 2025 08:00 CET Report this content
Sobi® will unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Mil... |
| 23.01.2025 | AstraZeneca's Solar Leap: A Bright Future for Sustainability | AstraZeneca is stepping into the future with a bold move. The pharmaceutical giant has partnered with Trinasolar and Smart Commercial Solar to transform its Sydney manufacturing site into a beacon of sustainability. This initiative is not j... |
| 21.01.2025 | Invitation: Sobi’s Q4 and FY 2024 report | Invitation: Sobi’s Q4 and FY 2024 report
Tue, Jan 21, 2025 13:00 CET Report this content
Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET.
Investors, analysts, and the media are i... |
| 21.01.2025 | Integrum welcomes new board members | Integrum welcomes new board members
Tue, Jan 21, 2025 21:19 CET Report this content
Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, welcomes the new board mem... |
| 10.01.2025 | Sobi's full year 2024 revenue higher than previous estimate | Sobi's full year 2024 revenue higher than previous estimate
Fri, Jan 10, 2025 18:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous e... |
| 08.01.2025 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report | Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care
LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ... |
| 07.01.2025 | BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial | BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
Tue, Jan 07, 2025 07:00 CET Report this content
Bergen, Norway, January 7, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical compan... |
| 18.12.2024 | The nomination committee in Integrum plans to propose the election of Anette Lindqvist as board member at an extraordinary general meeting | The nomination committee in Integrum plans to propose the election of Anette Lindqvist as board member at an extraordinary general meeting
Wed, Dec 18, 2024 15:07 CET Report this content
Integrum AB (publ), short name INTEG, the medical tec... |
| 11.12.2024 | Bulletin from Sobi’s Extraordinary General Meeting (EGM) | Bulletin from Sobi’s Extraordinary General Meeting (EGM)
Wed, Dec 11, 2024 09:30 CET Report this content
The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee’... |
| 03.12.2024 | Sobi’s strength in haematology to be showcased at ASH 2024 | Sobi’s strength in haematology to be showcased at ASH 2024
Tue, Dec 03, 2024 08:00 CET Report this content
New data from Sobi® and partners will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Dieg... |
| 14.11.2024 | Navigating the Future of Biopharma: Sobi's Meeting and TRexBio's Funding Surge | In the ever-evolving landscape of biopharmaceuticals, two significant events recently captured the industry's attention. Swedish Orphan Biovitrum AB (Sobi) announced an Extraordinary General Meeting, while TRexBio secured a hefty $84 millio... |
| 11.11.2024 | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Mon, Nov 11, 2024 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Ex... |
| 05.11.2024 | Sobi's New Leadership: A Strategic Shift in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, leadership changes can signal new directions and strategies. Recently, Swedish Orphan Biovitrum AB (Sobi) announced the nomination of David Meek as the new Chair of the Board of Directors. T... |
| 05.11.2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
| 04.11.2024 | David Meek is proposed as new Chair of the Board of Directors of Sobi | David Meek is proposed as new Chair of the Board of Directors of Sobi
Mon, Nov 04, 2024 21:00 CET Report this content
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of... |
| 30.10.2024 | New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference | New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Wed, Oct 30, 2024 08:00 CET Report this content
Sobi® (STO: SOBI) today announced that new research showing the effect of emapa... |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 26.10.2024 | Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN | Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
Sat, Oct 26, 2024 20:00 CET Report this content Statistically significant 68% (p |
| 25.10.2024 | Invitation: Sobi’s Aspaveli® and the Phase 3 VALIANT data in Nephrology call | Invitation: Sobi’s Aspaveli® and the Phase 3 VALIANT data in Nephrology call
Fri, Oct 25, 2024 13:00 CET Report this content
VALIANT Phase 3 results after presentation at ASN
Investors, analysts, and members of the media are invited to a co... |
| 24.10.2024 | Sobi Q3 2024 report: Strong growth and significant pipeline momentum | Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Thu, Oct 24, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024
Third Quarter 2024
• Total... |
| 09.10.2024 | Invitation: Sobi’s Q3 2024 report | Invitation: Sobi’s Q3 2024 report
Wed, Oct 09, 2024 13:00 CET Report this content
Sobi plans to publish its report for the third quarter of 2024 on 24 October 2024 at 08:00 CEST.
Investors, analysts, and the media are invited to a conferenc... |
| 30.09.2024 | New number of shares and votes in Sobi | New number of shares and votes in Sobi
Mon, Sep 30, 2024 08:00 CET Report this content
As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are common s... |
| 12.09.2024 | Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories | Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories
Thu, Sep 12, 2024 14:00 CET Report this content
Sobi® (STO: SOBI) and Enable Injections, Inc. (Enable) today ... |
| 29.08.2024 | Sobi has completed issues of class C shares | Sobi has completed issues of class C shares
Thu, Aug 29, 2024 14:45 CET Report this content
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible cl... |
| 21.08.2024 | Shifting Gears in Biotech: SciBase and AAX Biotech Make Strategic Moves | In the fast-paced world of biotechnology, change is the only constant. Companies must adapt, evolve, and sometimes pivot to stay relevant. Recently, two Swedish biotech firms, SciBase and AAX Biotech, made significant announcements that ref... |
| 21.08.2024 | AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team | AAX Biotech appoints Patrik Strömberg to Board of Directors, enhancing leadership team
Wed, Aug 21, 2024 07:30 CET Report this content
AAX Biotech is pleased to welcome Patrik Strömberg as new board member. Patrik Strömberg brings over two ... |
| 08.08.2024 | Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN | Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Thu, Aug 08, 2024 13:00 CET Report this content Met the primary endpoint, achieving statistically significant 68% (p |
| 18.07.2024 | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A
Thu, Jul 18, 2024 08:00 CET Report this content XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophyla... |
| 16.07.2024 | Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance | Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Tue, Jul 16, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2024
Second Quarter 202... |
| 15.07.2024 | The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under incentive programmes | The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under incentive programmes
Mon, Jul 15, 2024 19:15 CET Report this content
The Annual General Meeting of S... |
| 03.07.2024 | Invitation: Sobi’s Q2 2024 report | Invitation: Sobi’s Q2 2024 report
Wed, Jul 03, 2024 14:00 CET Report this content
Sobi plans to publish its report for the second quarter of 2024 on 16 July 2024 at 08:00 CEST.
Investors, analysts and media are invited to participate in a c... |
| 02.07.2024 | Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout | Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
Tue, Jul 02, 2024 08:00 CET Report this content
Sobi® today announced the initiation of a rolling Biologics Licen... |
| 19.06.2024 | European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A | European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Wed, Jun 19, 2024 08:00 CET Report this content
Sobi® today announced the European Commission has granted Marketing Authorisation for ALTU... |
| 17.06.2024 | Sobi to present new haemophilia data at ISTH 2024 | Sobi to present new haemophilia data at ISTH 2024
Mon, Jun 17, 2024 08:00 CET Report this content
Sobi® will present new scientific data related to haemophilia at ISTH 2024, the 32nd Congress of the International Society on Thrombosis and H... |
| 10.06.2024 | Sobi to present new data across its haematology portfolio at the 2024 EHA congress | Sobi to present new data across its haematology portfolio at the 2024 EHA congress
Mon, Jun 10, 2024 12:15 CET Report this content
Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid... |
| 24.05.2024 | Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress | Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress
Fri, May 24, 2024 16:05 CET Report this content Rapid reduction in disease activity seen at 12 weeks sustained at one year 55% of patients sho... |
| 14.05.2024 | Bulletin from Sobi’s Annual General Meeting (AGM) | Bulletin from Sobi’s Annual General Meeting (AGM)
Tue, May 14, 2024 16:45 CET Report this content
The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 14 May 2024. At the AGM, the shareholders, in accordance with the pro... |
| 08.05.2024 | Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH | Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
Wed, May 08, 2024 10:15 CET Report this content
Sobi® today announced that the European Commission (EC) has approved an indication extension ... |
| 08.05.2024 | Sobi has completed SEK 3 billion senior bond issue | Sobi has completed SEK 3 billion senior bond issue
Wed, May 08, 2024 11:24 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under it... |
| 08.05.2024 | Orexo Q1 2024 Interim Report | Orexo Q1 2024 Interim Report
Wed, May 08, 2024 08:00 CET Report this content
Starting 2024 with a positive EBITDA
Q1 2024 highlights
› Total net revenues of SEK 139.3 m (158.8)
› EBITDA of SEK 15.9 m (-41.1)
› Net earnings of SEK -8.9 m (-6... |
| 26.04.2024 | Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A | Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Fri, Apr 26, 2024 13:35 CET Report this content
Sobi® today announced the Committee for Medicinal Products for Human... |
| 26.04.2024 | Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus | Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Fri, Apr 26, 2024 10:30 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme wi... |
| 25.04.2024 | Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio | Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Thu, Apr 25, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
•... |
| 17.04.2024 | World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders" | MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is "Equitable access for all: recognizing all bl... |
| 15.04.2024 | Invitation: Sobi’s Q1 2024 report | Invitation: Sobi’s Q1 2024 report
Mon, Apr 15, 2024 10:00 CET Report this content
Sobi plans to publish its report for the first quarter of 2024 on 25 April 2024 at 08:00 CEST.
Investors, analysts and media are invited to participate in a c... |
| 04.04.2024 | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Thu, Apr 04, 2024 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual Ge... |
| 02.04.2024 | Sobi publishes Annual and sustainability report for 2023 | Sobi publishes Annual and sustainability report for 2023
Tue, Apr 02, 2024 11:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and sustainability report for 2023. Inspired by caring and powere... |
| 25.03.2024 | Sobi announces positive results from phase 3 study of Doptelet® for treatment of children and adolescents with ITP | Sobi announces positive results from phase 3 study of Doptelet® for treatment of children and adolescents with ITP
Mon, Mar 25, 2024 08:00 CET Report this content
The primary endpoint was met, confirming the efficacy and safety of avatrombo... |
| 13.02.2024 | Sobi and Handok establish joint venture for rare disease business in South Korea | Sobi and Handok establish joint venture for rare disease business in South Korea
Tue, Feb 13, 2024 07:00 CET Report this content
A long-term strategic partnership model is being developed through a joint venture.
The joint venture will comm... |
| 08.02.2024 | Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024 | Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
Thu, Feb 08, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023
Fourth Quarter ... |
| 31.01.2024 | Sobi to present new data at EAHAD 2024 | Sobi to present new data at EAHAD 2024
Wed, Jan 31, 2024 07:00 CET Report this content
Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders (EAHAD) conference in Frankfurt from 6-9 February 2024. ... |
| 24.01.2024 | Invitation: Sobi’s Q4 and FY 2023 report | Invitation: Sobi’s Q4 and FY 2023 report
Wed, Jan 24, 2024 10:00 CET Report this content
Sobi plans to publish its report for the fourth quarter and full year of 2023 on 8 February 2024 at 08:00 CET.
Investors, analysts, and media are invit... |
| 05.01.2024 | Sobi’s Chairman of the Board resigns due to health reasons | Sobi’s Chairman of the Board resigns due to health reasons
Fri, Jan 05, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB’s (publ) (Sobi®) (STO: SOBI) (“Sobi”) Chairman of the Board Bo Jesper Hansen resigns, at his own request ... |
| 30.11.2023 | Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) | Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Thu, Nov 30, 2023 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) (“Sobi”) has, as previously announced, carried out a share iss... |
| 20.11.2023 | Sobi to present new data at ASH 2023 Annual Meeting | Sobi to present new data at ASH 2023 Annual Meeting
Mon, Nov 20, 2023 08:00 CET Report this content
Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of ... |
| 01.11.2023 | Sobi has completed the issuances of series C shares | Sobi has completed the issuances of series C shares
Wed, Nov 01, 2023 18:00 CET Report this content
The Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) (“Sobi”) has, as previously communicated, on 31 October 202... |
| 31.10.2023 | Sobi issues series C shares to fulfil its obligations under outstanding incentive programmes | Sobi issues series C shares to fulfil its obligations under outstanding incentive programmes
Tue, Oct 31, 2023 18:00 CET Report this content
The Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) (“Sobi”) has, base... |
| 30.10.2023 | Sobi publishes Q3 2023 report: Strong revenue and solid performance | Sobi publishes Q3 2023 report: Strong revenue and solid performance
Mon, Oct 30, 2023 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2023
Third Quarter 2023
• Total ... |
| 27.10.2023 | Reminder: Invitation: Sobi’s Q3 2023 report | Reminder: Invitation: Sobi’s Q3 2023 report
Fri, Oct 27, 2023 11:00 CET Report this content
Sobi plans to publish its report for the third quarter of 2023 on 30 October 2023 at 08:00 CET.
Investors, analysts, and media are invited to partic... |
| 18.10.2023 | Invitation: Sobi’s Q3 2023 report | Invitation: Sobi’s Q3 2023 report
Wed, Oct 18, 2023 15:00 CET Report this content
Sobi plans to publish its report for the third quarter of 2023 on 30 October 2023 at 08:00 CET.
Investors, analysts, and media are invited to participate in a... |
| 17.10.2023 | Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G | Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G
Tue, Oct 17, 2023 13:15 CET Report this content After 12 weeks, 50% of patients treated with pegcetacoplan showed a redu... |
| 05.10.2023 | Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer | Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer
Thu, Oct 05, 2023 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced the appointment of Lydia Abad-Franch, MD, MBA... |
| 15.09.2023 | Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia | Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia
Fri, Sep 15, 2023 14:00 CET Report this content
18 September 2023
15:00 CEST, 14:00 BST, 09:00 EDT
Sobi invites investors to participate in a virtual KOL haemo... |
| 08.09.2023 | Sobi KOL investor event: Advancing the standard of care in haemophilia | Sobi KOL investor event: Advancing the standard of care in haemophilia
Fri, Sep 08, 2023 13:30 CET Report this content 18 September 2023 15:00 CEST, 14:00 BST, 09:00 EDT
Sobi invites investors to participate in a virtual KOL haemophilia eve... |
| 15.08.2023 | Bulletin from Swedish Orphan Biovitrum (Sobi)’s Extraordinary General Meeting (EGM) | Bulletin from Swedish Orphan Biovitrum (Sobi)’s Extraordinary General Meeting (EGM)
Tue, Aug 15, 2023 10:55 CET Report this content
The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the pro... |
| 18.07.2023 | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Tue, Jul 18, 2023 08:15 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Ex... |
| 18.07.2023 | Sobi publishes Q2 2023 report: Growth and pipeline expansion | Sobi publishes Q2 2023 report: Growth and pipeline expansion
Tue, Jul 18, 2023 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2023
Second quarter 2023 Total revenue... |
| 14.07.2023 | Sobi KOL investor event: the journey for Vonjo® | Sobi KOL investor event: the journey for Vonjo®
Fri, Jul 14, 2023 17:15 CET Report this content
19 July 2023
15:30 CEST, 14:30 BST, 09:30 EDT
Following the completion of Sobi’s acquisition of CTI Biopharma, Sobi’s management will host a vir... |
| 11.07.2023 | Invitation: Sobi’s Q2 2023 report | Invitation: Sobi’s Q2 2023 report
Tue, Jul 11, 2023 10:30 CET Report this content
Sobi plans to publish its report for the second quarter of 2023 on 18 July 2023 at 08:00 CEST.
Investors, analysts and media are invited to participate in a c... |
| 30.06.2023 | New number of shares and votes in Swedish Orphan Biovitrum AB (publ) | New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Fri, Jun 30, 2023 14:01 CET Report this content
As per 30 June 2023, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares... |
| 26.06.2023 | Sobi completes acquisition of CTI BioPharma Corp. | Sobi completes acquisition of CTI BioPharma Corp.
Mon, Jun 26, 2023 15:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATI... |
| 25.06.2023 | Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing | Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
Sun, Jun 25, 2023 16:45 CET Report this content
XTEND-Kids data confirms th... |
| 24.06.2023 | Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp. | Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
Sat, Jun 24, 2023 06:50 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM A... |
| 20.06.2023 | The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme | The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme
Tue, Jun 20, 2023 13:00 CET Report this content
The Annual General Meeting o... |
| 19.06.2023 | Changes to Sobi’s management | Changes to Sobi’s management
Mon, Jun 19, 2023 14:45 CET Report this content
Tony Hoos, Head of R&D and Medical Affairs (RDMA), and Chief Medical Officer (CMO), is leaving Sobi.
Lydia Abad-Franch, MD. MBA., currently Head of Medical Aff... |
| 14.06.2023 | Sobi to present new data at ISTH 2023 | Sobi to present new data at ISTH 2023
Wed, Jun 14, 2023 10:00 CET Report this content
Sobi® will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis. This event, taking plac... |
| 02.06.2023 | Sobi to present new data at the 2023 EHA congress | Sobi to present new data at the 2023 EHA congress
Fri, Jun 02, 2023 09:00 CET Report this content
Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023, high... |
| 25.05.2023 | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
Thu, May 25, 2023 13:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI... |
| 19.05.2023 | EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A | EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A
Fri, May 19, 2023 07:00 CET Report this content
Sobi today announced that the European Medicines Agency (EMA) has accepted and validated... |
| 12.05.2023 | Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal | CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule for additional indications. CTI expects ... |
| 10.05.2023 | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology
Wed, May 10, 2023 07:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... |
| 10.05.2023 | Sobi to Acquire CTI BioPharma, for Approx. $1.7 Billion | Swedish Orphan Biovitrum AB (STO: SOBI) (“Sobi”), a global healthcare leader in hematology, immunology and specialty care, is to acquire CTI BioPharma (Nasdaq: CTIC), a Seattle, WA-based commercial biopharmaceutical company focused on the d... |
| 09.05.2023 | Bulletin from Swedish Orphan Biovitrum (Sobi)’s Annual General Meeting (AGM) | Bulletin from Swedish Orphan Biovitrum (Sobi)’s Annual General Meeting (AGM)
Tue, May 09, 2023 16:55 CET Report this content
The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resol... |
| 27.04.2023 | Sobi publishes Q1 2023 report: Continued solid progress | Sobi publishes Q1 2023 report: Continued solid progress
Thu, Apr 27, 2023 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report
for the first quarter of 2023
First quarter 2023
• Total revenue S... |
| 19.04.2023 | Invitation: Sobi’s Q1 2023 report | Invitation: Sobi’s Q1 2023 report
Wed, Apr 19, 2023 11:00 CET Report this content
Sobi plans to publish its report for the first quarter of 2023 on 27 April 2023 at 08:00 CEST.
Investors, analysts and media are invited to participate in a c... |
| 09.04.2023 | Sobi to streamline nirsevimab contractual arrangements | Sobi to streamline nirsevimab contractual arrangements
Sun, Apr 09, 2023 18:00 CET Report this content
Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with Astra... |
| 03.04.2023 | Sobi® publishes Annual and sustainability report for 2022 | Sobi® publishes Annual and sustainability report for 2022
Mon, Apr 03, 2023 08:00 CET Report this content
Under the header of ‘Inspired by caring, powered by science’, Sobi® today published its Annual and sustainability report for 2022 with... |
| 30.03.2023 | Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thu, Mar 30, 2023 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual Ge... |
| 21.03.2023 | Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint | Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Tue, Mar 21, 2023 08:28 CET Report this content
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLV... |
| 02.03.2023 | Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A | Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A
Thu, Mar 02, 2023 08:00 CET Report this content
Primary endpoint was met with no factor VIII inhibitor... |